Mp22-14 Role of Metastasectomy in Post-Cystectomy Recurrence of Bladder Cancer: Single Institution Retrospective Study

You have accessJournal of UrologyBladder Cancer: Invasive II (MP22)1 May 2024MP22-14 ROLE OF METASTASECTOMY IN POST-CYSTECTOMY RECURRENCE OF BLADDER CANCER: SINGLE INSTITUTION RETROSPECTIVE STUDY Luis Santos Molina, Sanam Ladi Seyedian, Chirag Doshi, Gus Miranda, Hooman Djaladat, Anne Schuckman, and Siamak Daneshmand Luis Santos MolinaLuis Santos Molina , Sanam Ladi SeyedianSanam Ladi Seyedian , Chirag DoshiChirag Doshi , Gus MirandaGus Miranda , Hooman DjaladatHooman Djaladat , Anne SchuckmanAnne Schuckman , and Siamak DaneshmandSiamak Daneshmand View All Author Informationhttps://doi.org/10.1097/01.JU.0001008608.50694.4b.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Recurrence of urothelial carcinoma of the bladder (UCB) following radical cystectomy (RC) is associated with poor prognosis. While most patients are managed with systemic treatment, some present with an isolated site of recurrence questioning the role of salvage surgical resection. The objective of the study was to examine the characteristics and outcomes of patients undergoing salvage metastasectomy for treatment of recurrent UCB following RC to assess its viability as a treatment option. METHODS: Using our IRB-approved cystectomy database, we conducted a retrospective review for patients who had a recurrence of UCB following RC with curative intent between January 1971 and December 2021. Patients (pts) for whom salvage surgery was the first treatment after recurrence were included. Diagnosis of recurrence was confirmed through imaging and/or pathology. Pts with recurrence in multiple sites, upper tract, or urethra were excluded. Pts were categorized based on location of metastasis, and characteristics and outcomes reported. RESULTS: We identified 3458 pts who underwent RC with intent to cure for UCB of whom 1012 (29.3%) had recurrence post RC. 34 pts (25 males, 9 females) with a median age of 69 years met the inclusion criteria. The most common site of recurrence was lung (9), lymph node (LN)(8), and brain(7). The median time to recurrence was 11.2 months. All pts underwent salvage surgery, with 24 receiving additional treatment: 6 radiation (3 brain, 1 bone, 1 lung, 1 LN), 11 chemotherapy (5 lung, 5 LN, 1 pelvis), 4 radiation and chemotherapy (2 brain, 1 bone, 1 pelvis), 2 immunotherapy and chemotherapy (2 LN), and 1 with a combination of all three (bone). Following salvage surgery, overall median survival was 25.1 months and median survival for each site varied: LN 50.2 months, lungs 30.2 months, bone 30.3 months, brain 16.5 months, and pelvis 9.4 months. Additionally, one patient had metastasis to the liver and one to the adrenal gland who were disease free for 8.3 and 3.7 months, respectively, after salvage surgery. CONCLUSIONS: This exploratory analysis invites further investigation of the role of surgery alone or in combination with systemic therapy in the face of limited metastatic disease. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e347 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Luis Santos Molina More articles by this author Sanam Ladi Seyedian More articles by this author Chirag Doshi More articles by this author Gus Miranda More articles by this author Hooman Djaladat More articles by this author Anne Schuckman More articles by this author Siamak Daneshmand More articles by this author Expand All Advertisement PDF downloadLoading ...